Due to the specific potential clinical relevance of the use of olaparib-based combinations in pancreatic cancer and the fact that olaparib and TRAIL demonstrated the strongest synergistic effect in CAPAN1 and BRCA2/CIN, these cells were used for further mechanistic studies. The gene discussed is PDXP; the disease is familial pancreatic carcinoma.